Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid Withdrawal Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal

NCT00980044
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Tramadol, Placebo
Drug
Lead sponsor
Michelle Lofwall
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jun 10, 2026, 6:03 AM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jun 10, 2026, 6:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 10, 2026, 6:03 AM EDT
Completed No phase listed Observational

Opioid Physiology Project

NCT03462797
View directory record Official record
Conditions
Tolerance, Withdrawal, Addiction, Epigenetic Changes
Interventions
Not listed
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
87 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Tramadol to Reduce Opioid Withdrawal Symptoms

NCT00142896
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Tramadol, Naloxone, Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

NCT06442566
View directory record Official record
Conditions
Opioid Withdrawal, Chronic Pain
Interventions
Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

NCT04218240
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

NCT00723177
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
AV411, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 10, 2026, 6:03 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jun 10, 2026, 6:03 AM EDT
Withdrawn Phase 1 Interventional

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

NCT06711640
View directory record Official record
Conditions
Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions
LUCEMYRA (lofexidine) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Jackson Pediatric Acupressure for Opioid Tapering

NCT05025384
View directory record Official record
Conditions
Iatrogenic Withdrawal Syndrome
Interventions
Acupressure
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
34 Weeks and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jun 10, 2026, 6:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04214834
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Network
Eligibility
36 Weeks and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

NCT00032968
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Berkeley, California • Oxnard, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Cannabidiol for Opioid Withdrawal

NCT04238754
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine PRN, Morphine scheduled
Drug
Lead sponsor
Indiana University
Other
Eligibility
Up to 28 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
MN-166 (50 mg) First, Placebo First
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers

NCT02250664
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Very low nicotine content cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 70 Years
Enrollment
775 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00630201
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Los Angeles, California • National City, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Not applicable Interventional

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

NCT03971097
View directory record Official record
Conditions
Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
McKeesport, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01650649
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Activity Monitoring Assessment of Opiate Withdrawal - 4

NCT00000335
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jun 10, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jun 10, 2026, 6:03 AM EDT